Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001)

Summary

The purpose of this study is to evaluate the safety and preliminary efficacy of MK-1697. There are 2 parts in this study: dose escalation to determine the recommended phase 2 dose (RP2D) and confirm the RP2D (Part A) and cohort expansion to determine preliminary efficacy in participants with colorectal cancer (CRC) or head and neck squamous cell cancer (HNSCC) (Part B). No formal hypothesis testing will be done in this study.

Timeline

Start

2018-08-13

Primary completion

2020-02-18

Completion

2020-02-18

Outcome

Outcome not reported

Stopped (Business): “Business Reasons”

Drugs

Indications